Phaseline

Companies › Processa Pharmaceuticals

Processa Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Eniluracil (PCS6422)
Dihydropyrimidine dehydrogenase inhibitor
DPYDPhase 2Breast Cancer–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06568692Eniluracil (PCS6422)Phase 2Breast CancerOncologyJul 2026

From the company's SEC filings

Cash of $0m on 2026-06-30; operating cash outflow about $11m a year; runway about 0 months at that burn, to Jul 2026

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Targets

DPYD (1)

Companies with the same targets

–

Companies built like this

Moleculin Biotech Dogwood Therapeutics Atossa Therapeutics Curis CNS Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.